
Avillion appoints pharma veteran as chief executive
pharmafile | February 21, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Allison Jeynes-Ellis, Avillion
Drug development firm Avillion has appointed Dr Allison Jeynes-Ellis to be its chief executive.
By stepping into the role Jeynes-Ellis replaces Lewis Cameron who has left the company to pursue other opportunities.
Jeynes-Ellis has over 20 years of senior leadership experience in the pharma business managing various teams to focus on clinical development projects, in Europe and the US.
She is a founding member of Avillion’s management team and was formerly the company’s chief medical officer. Jeynes-Ellis has worked previously at Wyeth, Bristol-Myers Squibb, and Novartis; and as an independent consultant to some firms including CAT and Genentech, government bodies and medical research charities.
Jeynes-Ellis was also medical and innovation director at the Association of British Pharmaceutical Industry (ABPI). She is a currently a non-executive director of the Health Research Authority and BioCity, Scotland.
Genghis Lloyd-Harris, a non-executive director of Avillion and a partner at Abingworth, said: “We are delighted that Allison has accepted the role of chief executive. She has clearly demonstrated a range of skills that is well suited to driving the innovative clinical development model that Avillion operates.”






